SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.51-1.3%Jan 16 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (10838)3/4/2004 6:01:00 PM
From: Biomaven  Read Replies (2) of 52153
 
adding an IV infusion to a regular shot would be a non-starter

If the results are as convincing as the consensus now thinks they are, then that might change some minds.

I guess MS though is kind of different from say RA - there the benefits are immediate and tangible enough that people willingly go with Enbrel infusions. For MS you just don't get the same degree of feedback.

BTW, if BIIB ever munched ELN that paired short would really do well. Not sure how likely that is, but it certainly must have crossed BIIB's mind earlier this year.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News